This product is an oral hypoglycaemic agent and a representative α-glucosidase inhibitor. It acts in the gut by inhibiting α-glucosidase, the enzyme responsible for breaking down disaccharides into monosaccharides. This delays the digestion and absorption of sugars, thereby improving postprandial hyperglycaemia. It is particularly suitable for diabetic patients whose primary energy source is carbohydrates and who experience elevated blood glucose levels after meals.

Primary Indications

Improving post-meal hyperglycemia in diabetes patients

The Main Contraindication To Medication

1. Patients with severe ketoacidosis, diabetic coma, or those in the pre-coma stage. (As intravenous fluids and rapid insulin administration are required to correct hyperglycaemia, oral administration of this product is contraindicated.)

2. Patients with severe infections, those undergoing surgery, or those with severe trauma. (As insulin injection is necessary for glycaemic control, oral administration of this product is contraindicated.)

3. Patients with a history of allergy to any component of this product.

Tablet